Pacira Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Pacira BioSciences

04/08/2026 22:01

Pacira Biosciences Inc PCRX.OQ reported quarterly adjusted earnings of 73 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 74 cents.  The mean expectation of six analysts for the quarter was for earnings of 65 cents per share. Wall Street expected results to range from 52 cents to 76 cents per share.
Revenue rose 6.2% to $192.40 million from a year ago; analysts expected $190.82 million. 
Pacira Biosciences Inc's reported EPS for the quarter was 12 cents​.
The company reported quarterly net income of $4.65 million.
Pacira Biosciences Inc shares had risen by 6.1% this quarter and gained 4.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Pacira Biosciences Inc is $28.50, about 5.5% above its last closing price of $26.92
This summary was machine generated from LSEG data August 4 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.65
0.73
Beat
Mar. 31 2026 
0.56
0.60
Beat
Dec. 31 2025 
0.90
0.57
Missed
Sep. 30 2025 
0.65
0.70
Beat